China Pharma (CPHI) 10-K 30 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 24, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	China Pharma Holdings, Inc.
Trading Symbol	CPHI
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		8,458,094
Entity Public Float			$ 10,601,665
Amendment Flag	false
Entity Central Index Key	0001106644
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-34471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	73-1564807
Entity Address, Address Line One	Second Floor, No. 17, Jinpan Road
Entity Address, Address Line Two	Haikou
Entity Address, City or Town	Hainan Province
Entity Address, Country	CN
Entity Address, Postal Zip Code	570216
City Area Code	86
Local Phone Number	898-6681-1730
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Auditor Name	B F Borgers CPA PC
Auditor Location	Lakewood, Colorado
Auditor Firm ID	5041

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 2,029,971	$ 4,859,059
Banker’s acceptances	13,784	91,362
Trade accounts receivable, less allowance for doubtful accounts of $16,739,527 and $18,312,707, respectively	421,531	714,475
Other receivables, less allowance for doubtful accounts of $27,149 and $32,210, respectively	29,139	29,564
Advances to suppliers	444,637	471
Inventory	2,947,787	3,339,686
Prepaid expenses	77,697	58,792
Total Current Assets	5,964,546	9,093,409
Property, plant and equipment, net	9,973,065	13,280,559
Operating lease right of use asset	39,046	127,958
Intangible assets, net	1,807,486	147,841
TOTAL ASSETS	17,784,143	22,649,767
Current Liabilities:
Trade accounts payable	667,082	926,749
Accrued expenses	404,807	298,452
Other payables	2,390,063	1,884,161
Advances from customers	520,295	210,028
Borrowings from related parties	2,475,840	2,779,690
Operating lease liability	40,445	85,282
Current portion of lines of credit	2,440,915	4,328,936
Convertible, redeemable note payable, net of issue discount	3,800,000
Total Current Liabilities	12,739,447	10,513,298
Non-current Liabilities:
Convertible, redeemable note payable, net of issue discount		5,250,000
Operating lease liability, net of current portion		44,181
Deferred tax liability	754,698	824,407
Total Liabilities	13,494,145	16,631,886
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 7,490,896 shares and 4,733,956 shares issued and outstanding, respectively	74,909	47,340
Additional paid-in capital	28,853,520	25,645,367
Retained deficit	(36,211,496)	(32,238,655)
Accumulated other comprehensive income	11,573,065	12,563,829
Total Stockholders’ Equity	4,289,998	6,017,881
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 17,784,143	$ 22,649,767

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts (in Dollars)	$ 16,739,527	$ 18,312,707
Other receivables, less allowance for doubtful accounts (in Dollars)	$ 27,149	$ 32,210
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	7,490,896	4,733,956
Common stock, shares outstanding	7,490,896	4,733,956

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 8,104,092	$ 9,641,925
Cost of revenue	8,598,008	9,292,655
Gross (loss) profit	(493,916)	349,270
Operating expenses:
Selling expenses	1,069,785	1,495,007
General and administrative expenses	1,893,269	1,651,024
Research and development expenses	185,858	318,964
Bad debt benefit	(93,851)	(255,215)
Total operating expenses	3,055,061	3,209,780
Loss from operations	(3,548,977)	(2,860,510)
Other income (expense):
Interest income	10,755	3,035
Interest expense	(434,619)	(542,001)
Net other expense	(423,864)	(538,966)
Loss before income taxes	(3,972,841)	(3,399,476)
Income tax expense
Net loss	(3,972,841)	(3,399,476)
Other comprehensive income (loss) - foreign currency translation adjustment	(990,764)	218,383
Comprehensive loss	$ (4,963,605)	$ (3,181,093)
Loss per share:
Basic and diluted (in Dollars per share)	$ (0.76)	$ (0.74)
Weighted average shares outstanding (in Shares)	5,256,855	4,612,926

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Basic and diluted (in Dollars per share)	$ (0.76)	$ (0.74)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2020	$ 45,580	$ 24,452,684	$ (28,839,179)	$ 12,345,446	$ 8,004,531
Balance (in Shares) at Dec. 31, 2020	4,557,956
Stock option compensation		15,243			15,243
Issuance of common stock in lieu of compensation	$ 1,760	1,177,440			1,179,200
Issuance of common stock in lieu of compensation (in Shares)	176,000
Net loss for the year			(3,399,476)		(3,399,476)
Foreign currency translation adjustment				218,383	218,383
Balance at Dec. 31, 2021	$ 47,340	25,645,367	(32,238,655)	12,563,829	6,017,881
Balance (in Shares) at Dec. 31, 2021	4,733,956
Issuance of common stock for intangible assets	$ 15,522	1,691,930			1,707,452
Issuance of common stock for intangible assets (in Shares)	1,552,229
Issuance of common stock for services	$ 300	41,700			42,000
Issuance of common stock for services (in Shares)	30,000
Conversions of note payable to common stock	$ 11,747	1,438,253			1,450,000
Conversions of note payable to common stock (in Shares)	1,174,711
Stock option compensation		36,270			36,270
Net loss for the year			(3,972,841)		(3,972,841)
Foreign currency translation adjustment				(990,764)	(990,764)
Balance at Dec. 31, 2022	$ 74,909	$ 28,853,520	$ (36,211,496)	$ 11,573,065	$ 4,289,998
Balance (in Shares) at Dec. 31, 2022	7,490,896

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (3,972,841)	$ (3,399,476)
Depreciation and amortization	2,700,533	3,087,820
Bad debt benefit	(93,851)	(255,215)
Stock and stock option compensation	78,270	15,243
Original issue discount accretion		250,000
Changes in assets and liabilities:
Trade accounts and other receivables	(170,194)	(545,534)
Advances to suppliers	(459,959)	1,798
Inventory	689,104	1,011,905
Trade accounts payable	(187,734)	(332,779)
Other payables and accrued expenses	692,190	415,309
Advances from customers	339,659	(520,414)
Prepaid expenses	(24,722)	21,505
Net Cash Used in Operating Activities	(409,545)	(249,838)
Cash Flows from Investing Activities:
Purchases of property and equipment	(401,964)	(438,055)
Net Cash Used in Investing Activities	(401,964)	(438,055)
Cash Flows from Financing Activities:
Payments of construction term loan		(2,325,039)
Payments of line of credit	(2,140,921)	(2,526,542)
Proceeds from lines of credit	564,965
Borrowings and interest from related party	28,962	1,183,414
Repayments to related party	(223,013)	(562,659)
Proceeds from convertible redeemable debt		5,000,000
Proceeds from lines of credit		3,828,564
Net Cash (Used In) Provided By Financing Activities	(1,770,007)	4,597,738
Effect of Exchange Rate Changes on Cash	(247,572)	(8,439)
Net Increase in Cash, Cash Equivalents and Restricted Cash	(2,829,088)	3,901,406
Cash and Cash Equivalents at Beginning of Period	4,859,059	957,653
Cash, Cash Equivalents and Restricted Cash at End of Period	2,029,971	4,859,059
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	141,797	218,232
Supplemental Noncash Investing and Financing Activities:
Accounts receivable collected with banker’s acceptances	503,383	601,021
Inventory purchased with banker’s acceptances	575,713	565,079
Right-of-use assets obtained in exchange for operating lease obligations		168,606
Common stock issued for intangible assets	1,707,452
Common stock issued for compensation		$ 1,179,200

Organization and Significant Ac

Organization and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern As of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022 to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Reverse Stock Split Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. Accounting Estimates Cash and Cash Equivalents Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts. Advances to Suppliers and Advances from Customers Inventory – Leases – At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (“Short-Term Leases”). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. Valuation of Long-Lived Assets Property, Plant and Equipment Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company’s contracts are fixed price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon buyer’s designated carrier or the buyer picks up the goods at the Company’s warehouse. For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a liability on the accompanying balance sheet as “Advances from customers” as of December 31, 2022 and 2021, respectively. Cost of Revenues Research and Development Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy. Interest Rate Risk Basic and Diluted Loss per Common Share As of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock and the 126,667 shares issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. In 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the standard during fiscal 2021. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: December 31, December 31, 2022 2021 Raw materials 1,839,641 2,131,584 Work in process 557,146 622,380 Finished goods 551,000 585,722 Total Inventory $ 2,947,787 $ 3,339,686

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: December 31, December 31, 2022 2021 Permit of land use $ 404,427 $ 441,783 Building 9,391,433 10,258,885 Plant, machinery and equipment 27,780,585 30,122,235 Motor vehicle 438,138 337,375 Office equipment 308,847 278,892 Total 38,323,430 41,439,170 Less: accumulated depreciation (28,350,365 ) (28,158,611 ) Property, plant and equipment, net $ 9,973,065 $ 13,280,559 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $2,663,975 and $3,049,706 for the years ended December 31, 2022 and 2021, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval for any new medical formulas during the years ended December 31, 2022 and 2021 and no costs were reclassified from advances to intangible assets during the years ended December 31, 2022 and 2021, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $36,558 and $38,114 for the years ended December 31, 2022 and 2021, respectively which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. On November 28, 2022, the Company entered into a Technology Transfer Contract (the “Agreement”) with Chengdu Bonier Medical Technology Development Co., Ltd (“Bonier”). Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the “Utility Model Patent”) and applied for an invention patent (the “Invention Patent”) at the same time. Pursuant to the Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical invention and the Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services, with a term of ten years. Effective November 28, 2022 the Company issued 1,552,229 share of its common stock valued at $1,707,452 based on the closing market price of its common stock of $1.10 per share at that date. The Company recorded the amount as Intangible assets on the accompanying balance sheet at December 31, 2022. The value of the intangible asset will be amortized over its remaining useful life of approximately 9.7 years. The Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent on the successful authorization of the above mentioned Invention Patent. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the years ended December 31, 2022 and 2021, respectively. Intangible assets consisted solely of NMPA approved medical formulas as follows: December 31, December 31, 2022 2021 Gross carrying amount $ 6,554,628 $ 5,294,892 Accumulated amortization (4,747,142 ) (5,147,051 ) Net carrying amount $ 1,807,486 $ 147,841 The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows: Year Amount 2023 211,939 2024 211,939 2025 206,055 2026 176,632 2027 176,632 Thereafter 824,289 Total $ 1,807,486

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2022
Other Payables [Abstract]
OTHER PAYABLES	NOTE 5 – OTHER PAYABLES Other payables consisted of the following: December 31, December 31, 2022 2021 Compensation payable to officer 951,506 715,506 Compensation and interest to related parties $ 372,578 $ 327,033 Business taxes and other 1,065,979 841,622 Total Other Payables $ 2,390,063 $ 1,884,161

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company’s board of directors (“Board”) had previously advanced to the Company an aggregate amount of $1,354,567 as of December 31, 2022 and December 31, 2021 which is recorded as “Other Payables – Related Parties” on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense years ended December 31, 2022 and 2021 was $13,546 and $13,546, respectively. Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $372,578 and $327,033 as of December 31, 2022 and 2021, respectively. The Company received advances totaling $0 and $1,183,414 and repaid $223,013 and $562,659 of the advances during the years ended December 31, 2022 and 2021, respectively from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,121,273 and $1,425,123 and are recorded as Other payables – related parties on the accompanying condensed consolidated balance sheets as of December 31, 2022 and 2021, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is now due July 9, 2023. Total interest expense related to the loan for the years ended December 31, 2022 and 2021 was $28,962 and $30,194, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheet totaling $951,506 and $715,506 as of December 31, 2022 and 2021, respectively. As discussed more fully in Note 12, on September 9, 2021 an aggregate of $1,179,200 of compensation was converted into a total of 176,000 shares of common stock at the market price of $6.70 per share from the Company’s 2010 Long-Term Incentive Plan, as amended.

Lines of Credit and Constructio

Lines of Credit and Construction Loan Facility	12 Months Ended
	Dec. 31, 2022
Lines of Credit and Construction Loan Facility [Abstract]
LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY	NOTE 7 – LINES OF CREDIT AND CONSTRUCTION LOAN FACILITY Lines of Credit In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) was advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) was advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest expense under this facility for the years ended December 31, 2022 and 2021 was $12,063 and $44,629, respectively. The Company repaid the remaining RMB 5,900,000 and RMB 1,600,000 (approximately $0.85 and $0.23 million, respectively) during the year ended December 31, 2022 and 2021, respectively as per the repayment schedule in full satisfaction of the line of credit. On June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million), all of which has been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. The Company paid all principal and interest on June 21, 2022 and on June 22, 2022 entered into a new loan for the same principal amount bearing interest at 4.17% and due December 21, 2022. On December 21, 2022 the Company repaid the loan in full and entered into a new line of credit for an aggregate amount of RMB 7,300,000 (approximately $1.0 million) with interest payable monthly at a rate of 3.9%. The line of credit is payable in one year. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately $0.56 million) on December 30, 2022. The Company has RMB 3,500,000 (approximately $0.44 million) remaining to borrow on this line of credit. The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. In September, 2021 the Company repaid the line of credit in full. Also in September, 2021 the Company entered into a new line a credit in the amount of RMB 3,200,000 (approximately $0.8 million) on the same terms. The line of credit was due on September 2, 2022. The line of credit was paid in full on September 6, 2022. On September 9, 2022, the Company received a new line of credit in the same amount. The loan bears interest at a rate of 4.5% and is due on September 7, 2023. On July 12, 2021, the Company obtained a short-term loan of RMB 3 million (approximately US$460,000) from Haikou HaiHongXin microfinance Co., Ltd., with a monthly interest rate of 1.5%. The company paid off the loan in September 2021. Total interest paid on this loan was $0 and $16,051 for the years ended December 31, 2022 and 2021, respectively. This loan was guaranteed by Haikou Financing Guarantee Company. On September 18, 2021 the Company obtained a line of credit for RMB 10,000,000 (approximately $1.54 million) with Bank of China. The loan bears interest at the rate of 3.85% per annum. The line of credit was paid in full on the due date of September 18, 2022. On September 30, 2022 the Company received a new line of credit in the same amount. The loan bears interest at the rate of 3.45% and is due September 28, 2023. Principal payments required for the remaining terms of the lines of credit as of December 31, 2022 are as follows: Year Lines of Credit 2023 $ 2,440,915 $ 2,440,915 The Company obtained a construction loan facility from Bank of China, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility was for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. The interest rate was 5.39% during the year ended December 31, 2021. During the year ended December 31, 2021, the Company repaid all the remaining principal payments due under the loan in the amount of $2,325,039 (RMB 15,000,000). Fair Value of Lines of Credit

Convertible Note Payable

Convertible Note Payable	12 Months Ended
	Dec. 31, 2022
Convertible Note Payable [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 8 – CONVERTIBLE NOTE PAYABLE On November 17, 2021, the Company entered into a Securities Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note (the “Note”) to an institutional accredited investor Streeterville Capital, LLC (the “Investor”). The Note matures fifteen months after the purchase price of the Note is delivered from the Investor to the Company (the “Purchase Price Date”). The Note was due on February 17, 2023. The parties are in negotiation in extending the Note. No event of default has occurred as of the date herein. The Note has the original principal amount of $5,250,000 and Investor gave consideration of $5,000,000, reflecting original issue discount of $250,000. The transaction contemplated under the Agreement was closed on November 19, 2021 and the Company anticipates using the proceeds for general working capital purposes. The Note was convertible into 350,000 shares of the Company’s common stock at a price of $15.00 per share through April 19, 2022. Thereafter, the Note is convertible into 175,000 shares at a price of $30.00 per share. Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor’s consent for certain fundamental transactions such as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor’s prior written consent will be deemed an Event of Default. Investor may redeem all or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date upon three trading days’ notice, in cash or converting into shares of the Company’s common stock, at a price equal to 85% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor’s consent. At inception, the Note was redeemable into 881,143 shares based on the lowest volume weighted average price of $5.95817 on the inception date of November 19, 2021. As of December 31, 2022, the Note was convertible into 3,836,070 shares of common stock based on 85% of the lowest volume weighted average price of $0.9910 on that date. The original issue discount of $250,000 was fully earned at the inception of the Note, and accordingly was recognized as interest expense in the accompanying statement of operations for the year ended December 31, 2021. Total interest expense for the years ended December 31, 2022 and 2021 was $250,314 and $279,979, respectively. On March 21, 2022 the Investor delivered its notice of redemption for $100,000 of the Note at the lowest volume weighted average price of $3.113 during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 32,123 shares of common stock to the Investor on March 23, 2022. On March 30, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the price of $3.129, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 63,918 shares of common stock to the Investor on March 31, 2022. On June 9, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the price of $1.98, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 101,010 shares of common stock to the Investor on June 13, 2022. On August 3, 2022 the Investor delivered its notice of redemption for $200,000 of the Note and related interest at the conversion price of $1.755, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 113,960 shares of common stock to the Investor on August 4, 2022. On October 17, 2022 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the conversion price of $1.12, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 89,286 shares of common stock to the Investor on October 18, 2022. On December 1, 2022 the Investor delivered its notice of redemption for $100,000 of the Note and related interest at the conversion price of $0.829, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 120,627 shares of common stock to the Investor on December 2, 2022. On December 5, 2022 the Investor delivered its notice of redemption for $310,000 of the Note and related interest at the conversion price of $0.829, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 373,945 shares of common stock to the Investor on December 6, 2022. On December 13, 2022 the Investor delivered its notice of redemption for $90,000 of the Note and related interest at the conversion price of $0.91, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 98,901 shares of common stock to the Investor on December 14, 2022. On December 14, 2022 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.829, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 180,905 shares of common stock to the Investor on December 15, 2022.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the years ended December 31, 2022 and 2021, operating lease cost was $78,092 and $92,085, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $82,015 and $98,845, respectively. As of December 31, 2022 and 2021, the Company reported operating lease right of use assets of $39,046 and $127,958, respectively and operating use liabilities of $40,445 and $85,282, respectively. As of December 31, 2022, its operating leases had a weighted average remaining lease term of 0.50 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month periods ended December 31: 2023 $ 41,007 Total undiscounted cash flows 41,007 Less: Imputed interest (562 ) 40,445 Less: Operating lease liabilities, current portion (40,445 ) Operating lease liabilities, net of current portion $ - The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2022, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2019 through December 31, 2022 and the Chinese income tax return for the year ended December 31, 2022 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the years ended December 31, 2022 and 2021, respectively due to continued net losses of the Company. Following is a reconciliation of income taxes calculated at the federal statutory rates to the provision for income taxes: Years Ended December 31, 2022 2021 (Benefit) tax at statutory rate of 25% $ (973,717 ) $ (849,869 ) Prior year refund received - - Other, primarily the difference in U.S. tax rates 8,416 8,440 Change in valuation allowance 965,301 841,429 Income tax expense $ - $ - The temporary differences which give rise to the deferred income tax assets and liability are as follows: December 31, 2022 2021 Deferred income tax assets: Allowance for doubtful trade receivables $ 4,184,882 $ 4,578,177 Allowance for doubtful other receivables 6,787 8,052 Inventory obsolescence reserve 34,921 137,549 Stock compensation 3,201 3,201 Expenses not deductible in current year 1,087,328 1,187,760 Advances for intangible assets impairment 9,782,172 10,685,714 Lease liability, net 349 376 PRC net operating loss carry forward 5,036,114 5,779,437 U.S. net operating loss carry forward 1,849,800 1,602,243 Total deferred income tax assets 21,985,554 23,982,509 Valuation allowance (21,985,554 ) (23,982,509 ) Net deferred income tax asset $ - $ - Deferred income tax liability: Intangible assets $ 754,698 $ 824,407 As of December 31, 2022, the Company had net operating loss carryforwards for PRC tax purposes of approximately $20.1 million which are available to offset any future taxable income through 2026. Approximately $6.0 million of these carryforwards expired in December 2022. The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of December 31, 2022 and 2021. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,985,554 and $23,982,509 as of December 31, 2022 and 2021, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds as of December 31, 2022 and 2021. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 13,784 $ - $ 13,784 $ - Total $ 13,784 $ - $ 13,784 $ - Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 91,362 $ - $ 91,362 $ - Total $ 91,362 $ - $ 91,362 $ -

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS’ EQUITY The Company is authorized to issue 500,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board. According to relevant PRC laws, companies registered in the PRC, including the Company’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000 at December 31, 2022 and 2021. 2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 500,000 shares from 400,000 shares to 900,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated 2010 Long Term Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 500,000 shares from 900,000 to 1,400,000. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 1,400,000 shares of common stock. Through December 31, 2022, there were 490,000 shares of stock and stock options granted under the Plan. A total of 66,500 options were outstanding as of December 31, 2022 under the Plan. As such, there are 910,000 additional shares available for issuance under the Plan. On October 3, 2022 the Company issued 30,000 shares of common stock pursuant to a contract with a consultant to the Company for services. The Company recorded compensation expense totaling $42,000 based on the closing market price of its common stock of $1.40 per share on the issuance date. The contract also calls for the issuance of up to 90,000 additional shares of common stock contingent upon the achievement of certain milestones as described in the contract. At December 31, 2022 these milestones had not been met. On October 4, 2022 the Company issued an option to purchase 60,000 shares of common stock at an exercise price at $5.60 per share, under the Plan to the same consultant in the preceding paragraph. The Option vests immediately and expires on October 3, 2027. On September 9, 2021 the Company issued an aggregate of 176,000 fully vested shares of common stock at the price of $6.70 per share, representing the closing market price on that date to its Chairperson, Chief Executive Officer and Interim Chief Financial Officer under the Plan, as amended, to partially offset certain unpaid cash compensation totaling $1,179,200. Also on September 9, 2021 the Company issued an option to purchase 6,500 shares of common stock at an exercise price at $14.70 per share, under the Plan. The Option vests immediately and expires on September 9, 2024. On December 23, 2020 the Board approved the issuance of 200,000 shares of common stock from the Company’s 2010 Long-Term Incentive Plan, as amended for the partial conversion of unpaid compensation totaling $864,480 to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer. As of December 31, 2022, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Risks & Uncertainties

Risks & Uncertainties	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
RISKS & UNCERTAINTIES	NOTE 13 – RISKS & UNCERTAINTIES Current vulnerability due to certain concentrations For the year ended December 31, 2022, no customer accounted for more than 10% of sales and three customers accounted for 52.9%, 11.4% and 10.4% of accounts receivable. Two suppliers accounted for 21.7% and 11.1% of raw material purchases, and three different products accounted for 29.2%, 27.3% and 12.5% of revenue. For the year ended December 31, 2021, no customer accounted for more than 10% of sales and three customers accounted for 52.1%, 11.2% and 10.2% of accounts receivable. Three suppliers accounted for 24.8%, 12.7% and 11.8% of raw material purchases, and three different products accounted for 20.7%, 17.7% and 13.5% of revenue. Nature of Operations Impact from the New Coronavirus Global Pandemic (“COVID-19”) Economic environment - In addition, all of the Company’s revenue is denominated in the PRC’s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS On January 5, 2023 the Investor delivered its notice of redemption for $150,000 of the Note and related interest at the conversion price of $0.763, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 196,592 shares of common stock to the Investor on January 6, 2023. On January 18, 2023 the Investor delivered its notice of redemption for $250,000 of the Note and related interest at the conversion price of $0.763, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 327,654 shares of common stock to the Investor on January 19, 2023. On March 2, 2023 the Investor delivered its notice of redemption for $250,000 of the Note and related interest at the conversion price of $0.575, which was 85% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 434,783 shares of common stock to the Investor on March 9, 2023. Effective March 6, 2023 the Company implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and the Company’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of the Company’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for the years ended December 31, 2022 and 2021.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.
Liquidity and Going Concern	Liquidity and Going Concern As of December 31, 2022, the Company had cash and cash equivalents of $2.0 million and an accumulated deficit of $36.2 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,121,273 as of December 31, 2022 to provide working capital and enable the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Reverse Stock Split	Reverse Stock Split
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.
Accounting Estimates	Accounting Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Trade Accounts Receivable and Allowance for Doubtful Accounts	Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectible trade accounts receivable balances in the amount of $0 and $0 against the allowance for the years ended December 31, 2022 and 2021, respectively. Customer balances outstanding for more than one year are allowed for at a greater rate than more current balances when calculating the allowance for doubtful accounts.
Advances to Suppliers and Advances from Customers	Advances to Suppliers and Advances from Customers
Inventory	Inventory –
Leases	Leases – At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term including any options to extend the lease that the Company is reasonably certain to exercise. The Company calculates the present value of lease payments using an incremental borrowing rate as the Company’s leases do not provide an implicit interest rate. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less (“Short-Term Leases”). For any Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the condensed balance sheet. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets
Property, Plant and Equipment	Property, Plant and Equipment
Revenue Recognition	Revenue Recognition The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company’s contracts are fixed price and reflect standalone pricing for each item. Due to the nature of the products sold, there are no returns. Generally, the Company’s performance obligations are transferred to customers at a point in time, typically upon buyer’s designated carrier or the buyer picks up the goods at the Company’s warehouse. For all reporting periods, the Company has not disclosed the value of unsatisfied performance obligations for all product revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The Company has received advance deposits for orders less than one year. These advances total $520,295 and $210,028 and are recorded as a liability on the accompanying balance sheet as “Advances from customers” as of December 31, 2022 and 2021, respectively.
Cost of Revenues	Cost of Revenues
Research and Development	Research and Development
Credit Risk	Credit Risk The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors’ interests. The PRC promulgated a Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. Company bank accounts in China are not subject to a certain insurance coverage and will follow the provisions set forth in the PRC Bankruptcy Law should any bank where the Company has accounts declare bankruptcy.
Interest Rate Risk	Interest Rate Risk
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share As of December 31, 2022, the Company has potentially dilutive common shares related to the option to purchase 96,500 shares of common stock and the 126,667 shares issuable upon conversion of the Convertible Note Payable are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. In 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. The pronouncement will be effective for public business entities that are SEC smaller reporting company filers in fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the standard during fiscal 2021. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory [Abstract]
Schedule of inventory	December 31, December 31, 2022 2021 Raw materials 1,839,641 2,131,584 Work in process 557,146 622,380 Finished goods 551,000 585,722 Total Inventory $ 2,947,787 $ 3,339,686

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	December 31, December 31, 2022 2021 Permit of land use $ 404,427 $ 441,783 Building 9,391,433 10,258,885 Plant, machinery and equipment 27,780,585 30,122,235 Motor vehicle 438,138 337,375 Office equipment 308,847 278,892 Total 38,323,430 41,439,170 Less: accumulated depreciation (28,350,365 ) (28,158,611 ) Property, plant and equipment, net $ 9,973,065 $ 13,280,559
Schedule of estimated useful lives of the assets	Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets [Abstract]
Schedule of intangible assets	December 31, December 31, 2022 2021 Gross carrying amount $ 6,554,628 $ 5,294,892 Accumulated amortization (4,747,142 ) (5,147,051 ) Net carrying amount $ 1,807,486 $ 147,841
Schedule of aggregate annual amortization expense	Year Amount 2023 211,939 2024 211,939 2025 206,055 2026 176,632 2027 176,632 Thereafter 824,289 Total $ 1,807,486

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2022
Other Payables [Abstract]
Schedule of other payables	December 31, December 31, 2022 2021 Compensation payable to officer 951,506 715,506 Compensation and interest to related parties $ 372,578 $ 327,033 Business taxes and other 1,065,979 841,622 Total Other Payables $ 2,390,063 $ 1,884,161

Lines of Credit and Construct_2

Lines of Credit and Construction Loan Facility (Tables)	12 Months Ended
	Dec. 31, 2022
Lines of Credit and Construction Loan Facility [Abstract]
Schedule of principal payments	Year Lines of Credit 2023 $ 2,440,915 $ 2,440,915

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of operating lease liabilities	2023 $ 41,007 Total undiscounted cash flows 41,007 Less: Imputed interest (562 ) 40,445 Less: Operating lease liabilities, current portion (40,445 ) Operating lease liabilities, net of current portion $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes	Years Ended December 31, 2022 2021 (Benefit) tax at statutory rate of 25% $ (973,717 ) $ (849,869 ) Prior year refund received - - Other, primarily the difference in U.S. tax rates 8,416 8,440 Change in valuation allowance 965,301 841,429 Income tax expense $ - $ -
Schedule of temporary differences to deferred income tax assets and liability	December 31, 2022 2021 Deferred income tax assets: Allowance for doubtful trade receivables $ 4,184,882 $ 4,578,177 Allowance for doubtful other receivables 6,787 8,052 Inventory obsolescence reserve 34,921 137,549 Stock compensation 3,201 3,201 Expenses not deductible in current year 1,087,328 1,187,760 Advances for intangible assets impairment 9,782,172 10,685,714 Lease liability, net 349 376 PRC net operating loss carry forward 5,036,114 5,779,437 U.S. net operating loss carry forward 1,849,800 1,602,243 Total deferred income tax assets 21,985,554 23,982,509 Valuation allowance (21,985,554 ) (23,982,509 ) Net deferred income tax asset $ - $ - Deferred income tax liability: Intangible assets $ 754,698 $ 824,407

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value	Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 13,784 $ - $ 13,784 $ - Total $ 13,784 $ - $ 13,784 $ - Fair Value Measurements at Reporting Date Using Description December 31, Level 1 Level 2 Level 3 Banker’s acceptance notes $ 91,362 $ - $ 91,362 $ - Total $ 91,362 $ - $ 91,362 $ -

Organization and Significant _2

Organization and Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	May 25, 2005
Organization and Significant Accounting Policies (Details) [Line Items]
Cash and cash equivalents	$ 2,000,000
Accumulated deficit	36,200,000
Bad debt expense	93,851	$ 255,215
Uncollectible trade accounts receivable	0	0
Advances from customers	$ 520,295	$ 210,028
Purchase of common stock (in Shares)	96,500
Shares issuable upon conversion of the convertible note payable (in Shares)	126,667
Onny Investment Limited [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100%
Hainan Helpson Medical & Biotechnology Co., Ltd [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100%		100%
Management [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Working capital	$ 1,121,273

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Inventory [Abstract]
Raw materials	$ 1,839,641	$ 2,131,584
Work in process	557,146	622,380
Finished goods	551,000	585,722
Total Inventory	$ 2,947,787	$ 3,339,686

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expanse	$ 2,663,975	$ 3,049,706

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of property, plant and equipment - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Property Plant and Equipment [Abstract]
Permit of land use	$ 404,427	$ 441,783
Building	9,391,433	10,258,885
Plant, machinery and equipment	27,780,585	30,122,235
Motor vehicle	438,138	337,375
Office equipment	308,847	278,892
Total	38,323,430	41,439,170
Less: accumulated depreciation	(28,350,365)	(28,158,611)
Property, plant and equipment, net	$ 9,973,065	$ 13,280,559

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets	12 Months Ended
	Dec. 31, 2022
Permit of land use [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	40 years
Permit of land use [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	70 years
Building [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	20 years
Building [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	49 years
Plant, machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years
Plant, machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	10 years
Motor vehicle [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years
Motor vehicle [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	10 years
Office equipment [Member] | Minimum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	3 years
Office equipment [Member] | Maximum [Member]
Property, Plant and Equipment (Details) - Schedule of estimated useful lives of the assets [Line Items]
Estimated useful lives	5 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		12 Months Ended
	Nov. 28, 2022	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets [Abstract]
Intangible assets useful life, description		Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
Amortization expense relating to intangible assets		$ 36,558	$ 38,114
Stock issued (in Shares)	1,552,229
Common stock value	$ 1,707,452
Closing price of common stock (in Dollars per share)	$ 1.1
Intangible asset useful life		9 years 8 months 12 days
Service fee percentage		15%

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Intangible Assets [Abstract]
Gross carrying amount	$ 6,554,628	$ 5,294,892
Accumulated amortization	(4,747,142)	(5,147,051)
Net carrying amount	$ 1,807,486	$ 147,841

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of aggregate annual amortization expense	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of Aggregate Annual Amortization Expense [Abstract]
2023	$ 211,939
2024	211,939
2025	206,055
2026	176,632
2027	176,632
Thereafter	824,289
Total	$ 1,807,486

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of other payables - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Payables [Abstract]
Compensation payable to officer	$ 951,506	$ 715,506
Compensation and interest to related parties	372,578	327,033
Business taxes and other	1,065,979	841,622
Total Other Payables	$ 2,390,063	$ 1,884,161

Related Party Transactions (Det

Related Party Transactions (Details)		12 Months Ended
	Sep. 09, 2021 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 21, 2022	Jun. 22, 2022	Sep. 18, 2021	Jun. 25, 2021	Jun. 30, 2020	Jul. 08, 2019 USD ($)	Jul. 08, 2019 CNY (¥)
Related Party Transactions (Details) [Line Items]
Aggregate amount		$ 1,354,567
Interest rate		1%		3.90%	4.17%	3.85%	4.17%	4.05%
Interest expense		$ 13,546	$ 13,546
Other payables		372,578	327,033
Borrowings from related parties		1,121,273	1,425,123
Other payables		951,506	715,506
Aggregate Note payable	$ 1,179,200
Compensation converted	$ 176,000
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Received advance		0
Repaid advance		223,013
Chief Financial Officer [Member]
Related Party Transactions (Details) [Line Items]
Received advance			1,183,414
Repaid advance			562,659
Market price per share (in Dollars per share) | $ / shares	$ 6.7
Management [Member]
Related Party Transactions (Details) [Line Items]
Interest rate									4.35%	4.35%
Interest expense		$ 28,962	$ 30,194
Loan agreement to borrow cash									$ (738,379)	¥ 4,770,000

Lines of Credit and Construct_3

Lines of Credit and Construction Loan Facility (Details)			1 Months Ended				12 Months Ended
	Apr. 30, 2020 USD ($)	Apr. 30, 2020 CNY (¥)	Oct. 31, 2020 USD ($)	Oct. 31, 2020 CNY (¥)	Jul. 31, 2020 USD ($)	Jul. 31, 2020 CNY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 28, 2023	Sep. 07, 2023	Dec. 31, 2022 CNY (¥)	Dec. 30, 2022 USD ($)	Dec. 30, 2022 CNY (¥)	Dec. 21, 2022 USD ($)	Dec. 21, 2022 CNY (¥)	Jun. 22, 2022	Dec. 31, 2021 CNY (¥)	Sep. 30, 2021 USD ($)	Sep. 30, 2021 CNY (¥)	Sep. 18, 2021 USD ($)	Sep. 18, 2021 CNY (¥)	Jul. 12, 2021 USD ($)	Jul. 12, 2021 CNY (¥)	Jun. 25, 2021	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CNY (¥)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 CNY (¥)	Apr. 30, 2020 CNY (¥)	Jun. 21, 2013 USD ($)	Jun. 21, 2013 CNY (¥)
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Line of credit amount							$ 440,000						$ 560,000	¥ 3,800,000	$ 1,000,000	¥ 7,300,000			$ 800,000	¥ 3,200,000	$ 1,540,000	¥ 10,000,000					¥ 3,200,000				$ 13,000,000	¥ 80,000,000
Advance amount			$ 300,000	¥ 2,343,340
Interest rate							1%					1%			3.90%	3.90%	4.17%				3.85%	3.85%			4.17%			4.05%	4.05%
Total interest expense							$ 53,283	$ 21,528	$ 22,258
Interest rate							4.50%	5.39%				4.50%						5.39%
Interest amount							$ 0	$ 16,051
Principal Payments								2,325,039										¥ 15,000,000
Forecast [Member]
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Interest rate										3.45%
Interest rate											4.50%
Haikou HaiHongXin microfinance Co., Ltd., [Member]
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Interest rate																							1.50%	1.50%
Short-term loan																							$ 460,000	¥ 3,000,000
Bank of China [Member]
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Line of credit amount	$ 1,400,000																													¥ 10,000,000
Advance amount	$ 700,000	¥ 5,000,000			$ 400,000	¥ 3,000,000
Interest rate					4.25%	4.25%
Total interest expense							12,063	44,629
Repaid remaining amount							850,000	230,000				¥ 5,900,000						¥ 1,600,000
Interest amount							$ 54,923	15,582
Bank of Communications [Member]
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Line of credit amount												¥ 3,500,000																$ 1,200,000	¥ 8,500,000
Total interest expense								$ 54,294
China CITIC Bank [Member]
Lines of Credit and Construction Loan Facility (Details) [Line Items]
Line of credit amount																										$ 500,000
Advance amount			$ 100,000	¥ 856,660

Lines of Credit and Construct_4

Lines of Credit and Construction Loan Facility (Details) - Schedule of principal payments - Lines of Credit [Member]	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
2023	$ 2,440,915
Total	$ 2,440,915

Convertible Note Payable (Detai

Convertible Note Payable (Details)											1 Months Ended		12 Months Ended
	Dec. 14, 2022 USD ($) $ / shares shares	Dec. 13, 2022 USD ($) $ / shares	Dec. 05, 2022 USD ($) $ / shares	Dec. 01, 2022 USD ($) $ / shares	Oct. 17, 2022 USD ($) $ / shares	Aug. 03, 2022 USD ($) $ / shares	Jun. 09, 2022 USD ($) $ / shares	Apr. 19, 2022 $ / shares	Mar. 30, 2022 USD ($) $ / shares	Mar. 21, 2022 USD ($) $ / shares	Nov. 19, 2021 $ / shares shares	Nov. 17, 2021 USD ($)	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 15, 2022 shares	Dec. 06, 2022 shares	Dec. 02, 2022 shares	Oct. 18, 2022 shares	Aug. 04, 2022 shares	Jun. 13, 2022 shares	Mar. 31, 2022 shares	Mar. 23, 2022 shares
Convertible Note Payable [Abstract]
Notes matures												15 months
Original principal amount | $												$ 5,250,000
Investor consideration | $												5,000,000
Original issue discount | $												$ 250,000		$ 250,000
Note converted into common stock								350,000
Converted common stock price per share (in Dollars per share) | $ / shares								$ 15
Convertible note (in Shares) | shares													175,000
Convertible note conversion price (in Dollars per share) | $ / shares													$ 30
Interest accrues on note, description													Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
Redeem of outstanding note | $	$ 150,000	$ 90,000	$ 310,000	$ 100,000	$ 100,000	$ 200,000	$ 200,000		$ 200,000	$ 100,000			$ 500,000
Percentage of common stock price on weighted average price													85%
Note redeemable into shares (in Shares) | shares											881,143		3,836,070
Weighted average price (in Dollars per share) | $ / shares	$ 0.829	$ 0.91	$ 0.829	$ 0.829	$ 1.12	$ 1.755	$ 1.98		$ 3.129	$ 3.113	$ 5.95817		$ 85
Weighted average price (in Dollars per share) | $ / shares													$ 0.991
Total interest expense | $													$ 250,314	$ 279,979
Common stock issued to investor (in Shares) | shares	98,901														180,905	373,945	120,627		113,960	101,010		32,123
Weighted average price percentage	85%	85%	85%	85%	85%	85%	85%		85%
Common stock issued to investor (in Shares) | shares																					63,918
Common stock issued to investor (in Shares) | shares																		89,286

Leases (Details)

Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases (Textual)
Operating lease cost	$ 78,092	$ 92,085
Cash flows from operating leases	82,015	98,845
Operating lease right of use assets	39,046	127,958
Operating leases liabilities	$ 40,445	$ 85,282
Weighted average remaining lease term	6 months
Weighted average discount rate	4.75%

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease liabilities	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of Operating Lease Liabilities [Abstract]
2023	$ 41,007
Total undiscounted cash flows	41,007
Less: Imputed interest	(562)
Total	40,445
Less: Operating lease liabilities, current portion	(40,445)
Operating lease liabilities, net of current portion

Income Taxes (Details)

Income Taxes (Details) - USD ($)		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2022	Dec. 31, 2021
Income Taxes (Details) [Line Items]
Enterprise income tax rate		25%
Net operating loss carryforwards for PRC tax		$ 20,100,000
Net operating loss expiration, description		Approximately $6.0 million of these carryforwards expired in December 2022. The Company also has net operating losses for United States federal income tax purposes of approximately $8.7 million of which $5.1 million is available to offset future taxable income, if any, through 2039, and $3.7 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
Valuation allowance for deferred tax assets		$ 21,985,554	$ 23,982,509
Minimum [Member]
Income Taxes (Details) [Line Items]
U.S. federal corporate income tax rate	35%
Maximum [Member]
Income Taxes (Details) [Line Items]
U.S. federal corporate income tax rate	21%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]
(Benefit) tax at statutory rate of 25%	$ (973,717)	$ (849,869)
Prior year refund received
Other, primarily the difference in U.S. tax rates	8,416	8,440
Change in valuation allowance	965,301	841,429
Income tax expense

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes (Parentheticals)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of reconciliation of income taxes calculated at federal statutory rates to provision for income taxes [Abstract]
(Benefit) tax at statutory rate	25%	25%

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of temporary differences to deferred income tax assets and liability - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred income tax assets:
Allowance for doubtful trade receivables	$ 4,184,882	$ 4,578,177
Allowance for doubtful other receivables	6,787	8,052
Inventory obsolescence reserve	34,921	137,549
Stock compensation	3,201	3,201
Expenses not deductible in current year	1,087,328	1,187,760
Advances for intangible assets impairment	9,782,172	10,685,714
Lease liability, net	349	376
PRC net operating loss carry forward	5,036,114	5,779,437
U.S. net operating loss carry forward	1,849,800	1,602,243
Total deferred income tax assets	21,985,554	23,982,509
Valuation allowance	(21,985,554)	(23,982,509)
Net deferred income tax asset
Deferred income tax liability:
Intangible assets	$ 754,698	$ 824,407

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes	$ 13,784	$ 91,362
Total	13,784	91,362
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes
Total
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes	13,784	91,362
Total	13,784	91,362
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker’s acceptance notes
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)					12 Months Ended
	Oct. 04, 2022	Oct. 03, 2022	Sep. 09, 2021	Dec. 23, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 27, 2022	Dec. 15, 2022	Dec. 14, 2022	Dec. 06, 2022	Dec. 02, 2022	Aug. 04, 2022	Jun. 13, 2022	Mar. 23, 2022	Dec. 27, 2021
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized					500,000,000	500,000,000
Common stock, par value (in Dollars per share)					$ 0.001	$ 0.001
Preferred stock, shares authorized					5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)					$ 0.001	$ 0.001
After tax income, percentage					10%
Reserve account balances, percentage					50%
General and statutory capital reserves amount (in Dollars)					$ 8,145,000	$ 8,145,000
Common stock reserved shares							500,000								500,000
Total option outstanding					66,500
Additional shares available for issuance					910,000
Common stock pursuant		30,000
Compensation expense (in Dollars)		$ 42,000
Closing market price (in Dollars per share)	$ 1.5	$ 1.4
Additional shares of common stock (in Dollars)		$ 90,000
Purchase of common stock	60,000		6,500
Exercise price (in Dollars per share)	$ 5.6		$ 14.7
Fair value of options granted (in Dollars)	$ 36,270
Volatility rate	115.50%
Risk free interest rate	3.84%		0.75%
Expected life	2 years 6 months
Issuance of common stock								180,905	98,901	373,945	120,627	113,960	101,010	32,123
Fair value of options granted (in Dollars)			$ 15,243
Market price per share (in Dollars per share)			$ 6.7
Volatility rate			118.40%
Expected life			1 year 6 months
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Issuance of common stock			176,000
Price per share (in Dollars per share)			$ 6.7
Total unpaid cash compensation (in Dollars)			$ 1,179,200
2010 Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Common stock issued					1,400,000
Stock and stock option granted and outstanding					490,000
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock reserved shares							900,000								400,000
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Common stock reserved shares							1,400,000								900,000
Chairperson [Member]
Stockholders' Equity (Details) [Line Items]
Unpaid compensation (in Dollars)				$ 864,480
2010 Long-Term Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Issuance of common stock				200,000

Risks & Uncertainties (Details)

Risks & Uncertainties (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Sales Revenue, Net [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10%	10%
Number of customers		3
Sales Revenue, Net [Member] | Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	52.90%
Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	11.40%
Number of customers	3
Accounts Receivable [Member] | Customer One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10.40%
Accounts Receivable [Member] | Customer Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage		11.20%
Accounts Receivable [Member] | Customer Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage		10.20%
Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Number of suppliers	3	3
Revenue One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	29.20%	20.70%
Revenue Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	27.30%	17.70%
Revenue Three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	12.50%	13.50%
Suppliers One [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	2%	24.80%
Suppliers Two [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	21.70%	12.70%
Suppliers Two [Member] | Revenue One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	11.10%
Suppliers Three [Member] | Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage		11.80%
Accounts Receivable [Member] | Customer One [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage		52.10%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Mar. 02, 2023	Jan. 18, 2023	Jan. 05, 2023
Subsequent Events (Details) [Line Items]
Investor redemption	$ 250,000	$ 250,000	$ 150,000
Conversion price	$ 0.575	$ 0.763	$ 0.763
Weighted average price percentage	85%	85%	85%
Common stock investor	434,783	327,654	196,592